Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANCN Anchiano Therapeutics	$1.20 -2.4%	$21.77	$0.51 ▼ $10.55	$8.90M	0.93	3.15 million shs	34,195 shs
BRNS Barinthus Biotherapeutics	$0.89 +1.6%	$0.88	$0.64 ▼ $1.65	$35.50M	-0.78	36,710 shs	10,861 shs
MDCX Medicus Pharma	$2.58 +0.4%	$4.28	$1.80 ▼ $8.94	$34.88M	N/A	424,208 shs	120,773 shs
XLO Xilio Therapeutics	$0.66 -1.4%	$0.78	$0.62 ▼ $1.70	$34.44M	-0.01	1.41 million shs	600,174 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANCN Anchiano Therapeutics	-2.44%	-7.69%	-12.41%	-11.11%	+41.19%
BRNS Barinthus Biotherapeutics	+1.59%	-9.15%	+5.18%	-11.49%	-44.81%
MDCX Medicus Pharma	+0.39%	-3.37%	-66.84%	-26.07%	+257,999,900.00%
XLO Xilio Therapeutics	-0.68%	-4.68%	-24.93%	-15.74%	-30.24%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANCN Anchiano Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BRNS Barinthus Biotherapeutics	2.3037 of 5 stars	3.5	3.0	0.0	0.0	0.6	0.8	1.3
MDCX Medicus Pharma	1.8079 of 5 stars	3.8	0.0	0.0	0.0	2.0	0.8	0.0
XLO Xilio Therapeutics	3.606 of 5 stars	3.5	5.0	0.0	0.0	3.2	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANCN Anchiano Therapeutics	0.00	N/A	N/A	N/A
BRNS Barinthus Biotherapeutics	3.00	Buy	$6.25	599.11% Upside
MDCX Medicus Pharma	3.50	Strong Buy	$23.50	810.85% Upside
XLO Xilio Therapeutics	3.00	Buy	$4.00	505.51% Upside

Current Analyst Ratings Breakdown

Latest ANCN, BRNS, MDCX, and XLO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/9/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
5/29/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
5/22/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00 ➝ $27.00
5/12/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$14.00 ➝ $27.00
5/8/2025	MDCX Medicus Pharma	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $20.00
4/28/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
4/21/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
4/14/2025	MDCX Medicus Pharma	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/14/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$14.00
3/24/2025	BRNS Barinthus Biotherapeutics	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/21/2025	BRNS Barinthus Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00 ➝ $3.00

(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANCN Anchiano Therapeutics	N/A	N/A	N/A	N/A	$2.01 per share	N/A
BRNS Barinthus Biotherapeutics	$14.97M	2.41	N/A	N/A	$3.23 per share	0.28
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	$0.29 per share	N/A
XLO Xilio Therapeutics	$6.34M	5.40	N/A	N/A	$0.40 per share	1.65

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANCN Anchiano Therapeutics	-$27.12M	-$3.46	8.00	N/A	N/A	N/A	36.08%	27.40%	N/A
BRNS Barinthus Biotherapeutics	-$61.07M	-$1.64	N/A	N/A	N/A	N/A	-46.43%	-38.50%	8/6/2025 (Estimated)
MDCX Medicus Pharma	-$11.16M	-$1.16	N/A	N/A	N/A	N/A	-380.03%	-224.22%	6/27/2025 (Estimated)
XLO Xilio Therapeutics	-$58.24M	-$0.84	N/A	N/A	N/A	-585.54%	-262.69%	-64.01%	8/14/2025 (Estimated)

Latest ANCN, BRNS, MDCX, and XLO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	XLO Xilio Therapeutics	$0.10	-$0.18	-$0.28	-$0.18	$42.00 million	$2.93 million
5/12/2025	Q1 2025	MDCX Medicus Pharma	-$0.23	-$0.42	-$0.19	-$0.42	N/A	N/A
5/7/2025	Q1 2025	BRNS Barinthus Biotherapeutics	-$0.34	-$0.49	-$0.15	-$0.49	N/A	N/A
3/28/2025	Q4 2024	MDCX Medicus Pharma	-$0.32	-$0.18	+$0.14	-$0.18	N/A	N/A
3/20/2025	Q4 2024	BRNS Barinthus Biotherapeutics	-$0.50	-$0.51	-$0.01	-$0.51	N/A	$14.97 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANCN Anchiano Therapeutics	N/A	N/A	N/A	N/A	N/A
BRNS Barinthus Biotherapeutics	N/A	N/A	N/A	N/A	N/A
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	N/A
XLO Xilio Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANCN Anchiano Therapeutics	N/A	3.25	3.25
BRNS Barinthus Biotherapeutics	N/A	9.18	9.18
MDCX Medicus Pharma	N/A	1.53	1.53
XLO Xilio Therapeutics	N/A	1.96	1.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANCN Anchiano Therapeutics	9.05%
BRNS Barinthus Biotherapeutics	25.20%
MDCX Medicus Pharma	N/A
XLO Xilio Therapeutics	54.29%

Insider Ownership

Company	Insider Ownership
ANCN Anchiano Therapeutics	6.88%
BRNS Barinthus Biotherapeutics	10.70%
MDCX Medicus Pharma	N/A
XLO Xilio Therapeutics	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANCN Anchiano Therapeutics	16	7.42 million	N/A	Not Optionable
BRNS Barinthus Biotherapeutics	107	40.34 million	36.02 million	N/A
MDCX Medicus Pharma	N/A	13.57 million	N/A	N/A
XLO Xilio Therapeutics	70	51.78 million	49.09 million	Not Optionable

ANCN, BRNS, MDCX, and XLO Headlines

Recent News About These Companies

Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Update

June 16 at 1:34 AM | americanbankingnews.com

Xilio Therapeutics expands board, elects new director

June 13, 2025 | investing.com

Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to Board of Directors

June 10, 2025 | quiverquant.com

Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors

June 10, 2025 | globenewswire.com

Xilio Therapeutics Announces Closing of $50.0 Million Public Offering

June 5, 2025 | globenewswire.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 3, 2025 | globenewswire.com

Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering

June 2, 2025 | globenewswire.com

Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite ...

June 2, 2025 | stockhouse.com

Xilio Therapeutics, Inc. Announces Proposed Underwritten Public Offering of Pre-Funded Warrants and Series A, B, and C Warrants

June 2, 2025 | quiverquant.com

Xilio Therapeutics Announces Proposed Public Offering

June 2, 2025 | globenewswire.com

Xilio Therapeutics, Inc. (XLO) Reports 26% Response in Colon Cancer Drug Trial

May 31, 2025 | insidermonkey.com

Xilio Therapeutics Reports Preliminary 26% Objective Response Rate in Phase 2 Trial of Vilastobart Combined with Atezolizumab for Metastatic MSS Colorectal Cancer

May 31, 2025 | quiverquant.com

Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer

May 31, 2025 | globenewswire.com

Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results

May 8, 2025 | finanznachrichten.de

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results

May 8, 2025 | finance.yahoo.com

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results

May 8, 2025 | globenewswire.com

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 2, 2025 | globenewswire.com

Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting

April 23, 2025 | globenewswire.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 4, 2025 | globenewswire.com

Xilio Therapeutics reports Q4 EPS (20c) vs (64c) last year

March 11, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANCN, BRNS, MDCX, and XLO Company Descriptions

Anchiano Therapeutics NASDAQ:ANCN

Anchiano Therapeutics Ltd., a preclinical biotechnology company, discovers, develops, and commercializes small molecule anti-cancer therapies. It primarily develops Pan-RAS Program that identifies novel indene-based small molecules that exhibit potent and selective inhibition of activated RAS signaling regardless of isoform or mutation; and PDE10/Ã-catenin program, which identifies small molecules that selectively and potently inhibit PDE10 and suppress Wnt/APC/Ã-catenin signaling in preclinical models. Anchiano Therapeutics Ltd. has collaboration and license agreement with ADT Pharmaceuticals, LLC to research and develop programs related to the pan-RAS and PDE10/Ã-catenin programs. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd. in July 2018. Anchiano Therapeutics Ltd. was founded in 2004 and is headquartered in Cambridge, Massachusetts.

Barinthus Biotherapeutics NASDAQ:BRNS

$0.89 +0.01 (+1.59%)

Closing price 06/18/2025 03:52 PM Eastern

Extended Trading

$0.91 +0.02 (+2.01%)

As of 06/18/2025 07:40 PM Eastern

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.

Medicus Pharma NASDAQ:MDCX

$2.58 +0.01 (+0.39%)

As of 06/18/2025 04:00 PM Eastern

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.

Xilio Therapeutics NASDAQ:XLO

$0.66 -0.01 (-1.40%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$0.69 +0.03 (+4.90%)

As of 06/18/2025 07:53 PM Eastern

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time